Trump announces drug pricing deal with Regeneron under most-favored-nation initiative
President Trump announced a deal with Regeneron on Thursday in which the drugmaker agreed to lower prices for its current and future medications as part of the White House's most-favored-nation drug pricing initiative. Regeneron is the last of 17 major pharmaceutical companies contacted by the administration to reach such an agreement. The deal includes Regeneron committing $27 billion to U.S. research, development, and manufacturing.
52
Divergence score
This event sits in the top 4% of divergence this week. 6 outlets covered it, splitting into 5 framing camps across 2 bias groups.
5 camps
2 bias groups
Market signalBETA
The spectrum · how 5 outlets placed this story
LeftCenterRight
The Hill
PBS NewsHour
Washington Examiner
Breitbart
Axios
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Breitbart frames the deal as an "Ame...
How each outlet covered it
Fact ledger · what actually happened, cross-checked